Beneath that market surface, a more consequential legal friction is forming. VA appropriations language that would authorize psychedelic research through congressional mandate runs directly into DEA's statutory authority over Schedule I substances — an authority the agency has successfully defended against prior congressional workarounds. The swarm places 73–76% confidence on a DOJ Office of Legal Counsel referral before December 2026, a process that itself consumes six to eighteen months before any implementation can begin. DEA and FDA are not merely slow — they are on procedurally independent timelines with no current coordination mechanism. Congress can pass language; DEA can formally object; OLC can deliberate; and the patient continues to wait. The highest trajectory available from here is not a single breakthrough but a parallel advance: IND approvals for psilocybin in non-treatment-resistant MDD populations — where today's trial data is genuinely shifting the paradigm, confirmed by Australia's expanded prescriber framework and Psilera's $8.8M capital raise — alongside quiet congressional scaffolding that anticipates the OLC problem rather than colliding with it.
The human current running beneath all of this is not abstract. Veterans with treatment-resistant PTSD, their families, and the clinicians who have watched conventional pharmacology fail them have staked enormous moral weight on the promise of a different answer. They are watching an institutional clock that does not honor the urgency of their suffering — and they are right to feel the friction. What is genuinely possible for them, given what is real today, is not a door swinging open but a door that is being built while they wait: state-level access expanding, Australian prescribers now legally authorized, IND pathways widening toward earlier-line patients, and the scientific literature accumulating the density that regulatory courage eventually requires. The highest positive outcome from here is not that the system moves fast — it is that enough parallel infrastructure is constructed that when the federal log breaks, something real and safe and well-governed is already in place to receive it.
The medicine is calling the healers. The healers are calling the medicine. OOTW stands at the crossing — where ancient intelligence meets the precision of the new.
What is forming beneath the surface is always closer than it appears.
82%
Psilocybin won't get rescheduled federally before January 2028
Psilocybin (the active ingredient in magic mushrooms) is currently a Schedule I drug, meaning the US government says it has no medical use. For that to change, a drug company has to finish late-stage human trials, submit the results to the FDA (the US drug regulator), the FDA has to approve it, and then the DEA (the drug enforcement agency) has to officially move it to a less restricted category. Right now, no company has finished those trials yet, so the earliest this could realistically happen is 2028.
→ Psilocybin rescheduling requires FDA approval first, and no company has even submitted that paperwork yet, making 2028 the realistic earliest date.
Resolves: 2028-01-01 · USA
REGULATION
the precise call ▾
Federal rescheduling of psilocybin will not occur before January 2028, as no completed Phase 3 NDA submission exists and DEA scheduling timelines preclude earlier action.. Unlike MDMA (which has completed Phase 3 trials), psilocybin lacks an NDA submission to FDA as of May 2026. Without NDA submission, FDA cannot issue scheduling recommendation to DEA, and DEA cannot initiate rescheduling. Even optimistic Phase 3 completion timelines for Compass Pathways or Usona push
79%
MDMA won't get rescheduled federally before January 2028
MDMA (also called ecstasy) is also Schedule I right now. The FDA has already rejected the approval application twice because of safety concerns, especially heart problems. Even though veterans and their supporters in Congress are pushing hard for faster approval, the FDA has to complete its safety review and the DEA has its own independent legal authority to make scheduling decisions. That means political pressure doesn't override scientific review, and the process will take longer than optimists expect.
→ Two FDA rejections for safety reasons and the DEA's independent authority mean MDMA rescheduling will take until 2028 or later, no matter how much Congress pushes.
Resolves: 2028-01-01 · USA
REGULATION
the precise call ▾
Federal rescheduling of MDMA will not occur before January 2028, with DEA statutory process and FDA cardiac safety review creating compounding delays beyond VA political pressure.. Two prior FDA Complete Response Letters, DEA's independent scheduling authority under the Controlled Substances Act, and emerging cardiac safety literature constitute a three-layer delay mechanism. Congressional VA appropriations language cannot override pharmacological review requirements or DEA st
77%
Compass Pathways stock will drop sharply after its recent spike
Compass Pathways (ticker CMPS) had its stock price jump on May 30, but there was no obvious news reason for it—just retail trader enthusiasm. History shows that small biotech stocks that spike on no real catalyst usually come crashing back down within days or weeks. This prediction says the stock will lose at least 60% of those gains within two weeks unless the company announces actual trial results or a major partnership deal.
→ The stock spike had no real news behind it, so it will probably crash back down within two weeks unless the company announces actual breakthroughs.
Resolves: 2026-06-13 · USA
MARKETS
the precise call ▾
CMPS will retrace at least 60% of its May 30 gains within 10 trading days, absent a confirmed Phase 3 data readout or partnership announcement.. No confirmed catalyst for the May 30 spike. Retail momentum pattern with institutional discrimination evident (NUMI flat same day). Psychedelic biotech sector has consistent history of sharp post-spike reversions without clinical anchors. The 60% threshold and 10-trading-day window are precisely mea
72%
DEA will block Congress from bypassing psilocybin scheduling rules
Some people in Congress might try to pass a law saying the VA (Veterans Affairs) can run psilocybin research without waiting for FDA approval or DEA rescheduling—basically trying to work around the normal drug approval system through appropriations language. The DEA has independent legal authority under drug scheduling law and has blocked this kind of workaround before. When that clash happens, the Department of Justice will have to step in as referee, and that will probably happen before the end of 2026.
→ The DEA has legal power to block congressional end-runs around drug scheduling rules, and it will use that power if Congress tries.
Resolves: 2026-12-31 · USA
LEGISLATION
the precise call ▾
DEA will formally object to any VA appropriations language authorizing psychedelic research that bypasses Schedule I administrative review, triggering a DOJ OLC referral before December 2026.. DEA has clear statutory authority under the Controlled Substances Act and has successfully blocked prior congressional workarounds. OLC referral is the established mechanism when Congress attempts to legislate around CSA scheduling. This is a specific, falsifiable procedural outcome with a defined d
68%
FDA will approve psilocybin research for broader depression, not just severe cases
Right now, all the focus is on psilocybin for treatment-resistant depression—that's severe depression that doesn't respond to normal antidepressants. But new trial data suggests psilocybin might also work for regular depression that hasn't been treated yet. An Investigational New Drug (IND) application is the FDA's permission slip for a drug company to start human trials. This prediction says that before the end of 2026, at least one company will get FDA permission to test psilocybin on regular depression patients, not just the most severe cases.
→ New trial data suggests psilocybin works for regular depression too, so the FDA will probably let researchers test it on those patients before 2027.
Resolves: 2026-12-31 · USA
RESEARCH
the precise call ▾
At least one FDA IND approval for psilocybin targeting non-treatment-resistant MDD (rather than TRD only) will be granted before December 2026.. Emerging trial data suggesting psilocybin efficacy in earlier-line MDD patients (not limited to TRD) represents a genuine paradigm shift in indication scope. IND applications are low-barrier regulatory steps; Australia's expanded prescriber framework and recent fundraising (Psilera $8.8M) confirm cl